Alzheimer's Disease

Found 820 articles

• Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity ConferenceMarch 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s Disease

  3/23/2023

  Vaccinex, Inc. today announced its COO and Senior Vice President, Discovery and Translational Medicine, Elizabeth Evans, PhD, will be making a podium presentation at the AAIC Advancements: Immunity conference.

• Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease

  3/22/2023

  Cognito Therapeutics announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors.

• Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

  3/22/2023

  Alzamend Neuro, Inc. today announced the completion of the clinical portion of its Phase IIA multiple ascending dose (“ MAD ”) study for dementia related to Alzheimer’s.

• Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD™ 2023 Annual Meeting

  3/22/2023

  Eisai Co., Ltd. announced the company will present the latest findings on lecanemab, Eisai's anti-amyloid beta protofibril* antibody for the treatment of Alzheimer's disease, at the 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders from March 28-April 1 in Gothenburg, Sweden and virtually.

• Alzheon to Present Biomarker, Brain Preservation and Clinical Effects of Oral Tablet ALZ-801 (Valiltramiprosate) at Upcoming AD/PD 2023 Conference in Gothenburg, Sweden

  3/22/2023

  Alzheon, Inc. announced that it will be presenting interim findings from an ongoing Phase 2 study evaluating ALZ-801 tablet at the upcoming AD/PD 2023 Conference to be held from March 28 – April 1, 2023 in Gothenburg, Sweden.

• IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

  3/20/2023

  India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma’s strategic focus and vision for the future.

• Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting

  3/14/2023

  Prothena Corporation plc announced broad participation at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders being held March 28 – April 1, 2023 in Gothenburg, Sweden, highlighting Prothena's leadership in advancing next generation treatments for Alzheimer’s and Parkinson’s disease.

• ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

  3/13/2023

  ProMIS Neurosciences Inc. today announced an oral presentation and two onsite poster presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, which will be held on April 22-27, 2023 in Boston, MA.

• ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

  3/13/2023

  ProMIS Neurosciences Inc. today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be presented as a virtual short oral poster presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) to be held on March 28-April 1, 2023 virtually and in Gothenburg, Sweden.

• 

  Lilly’s Alzheimer’s Struggles Continue as Preclinical Disease Asset Fails Phase III

  3/9/2023

  Data released Wednesday from the Phase III A4 study showed solanezumab fell short of its primary endpoint, failing to slow cognitive decline in patients with preclinical Alzheimer’s disease.

• SYNAPS Dx Brings El Paso, Texas Marketplace First Highly Accurate Diagnostic Alzheimer’s Disease Test for Patients Diagnosed with Dementia

  3/8/2023

  SYNAPS Dx is pleased to announce that the Advanced Neurology, Epilepsy and Sleep Centers with locations in the El Paso, Texas area will be among the first in the country to offer area residents access to DISCERN™, a minimally invasive diagnostic test.

• Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease

  3/8/2023

  Eli Lilly and Company (NYSE:LLY) announced today that solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease (AD) pathology when initiated in individuals with amyloid plaque but no clinical symptoms of the disease, known as the preclinical stage of AD1.

• ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

  3/8/2023

  Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration Preclinical data that further characterize ongoing programs, including PMN310, to be presented in 2023.

• AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration

  3/8/2023

  Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions.

• AlzeCure Participates at Redeye Alzheimer Seminar on March 15

  3/7/2023

  AlzeCure Pharma AB announced that the company is participating at Redeye Alzheimer Seminar on March 15 at 14:10 CET, where CEO Martin Jönsson will present and answer questions about the latest development in the company.

• 

  FDA Sets July Decision Date for Full Approval of Leqembi

  3/6/2023

  The FDA set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi, Eisai announced Monday.

• FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease and grants Priority Review: BioArctic

  3/6/2023

  BioArctic AB's partner Eisai announced that the U.S. Food and Drug Administration has accepted Eisai's supplemental Biologics License Application for LEQEMBI™ 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval.

• Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

  3/6/2023

  Athira Pharma, Inc. today announced that it will participate in two upcoming scientific conferences: American Society for Experimental Neurotherapeutics (ASENT) 2023 Annual Meeting, which will be held virtually from Mar. 13-15, 2023.

• FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

  3/5/2023

  Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration has accepted Eisai’s supplemental Biologics License Application for LEQEMBI™ 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval.

• BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease

  3/2/2023

  BioVie Inc. today announced that its NM101 trial evaluating NE3107 in the treatment of patients with Alzheimer’s Disease, has achieved its revised enrollment target of 400 patients.